Literature DB >> 17355517

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.

J Eberhard1, E Lindström, M Holstad, S Levander.   

Abstract

OBJECTIVE: To investigate prolactin levels and related side effects in 128 men and 90 women initially treated with risperidone.
METHOD: Patients initially treated with risperidone were followed over 5 years, during which 45% were switched to other antipsychotic drugs.
RESULTS: Initially, prolactin levels were fivefold the norm in women, and threefold in men. Diagnosis did not affect the prolactin level if adjustment for sex, current age, and age at onset of psychosis was applied. Prolactin levels did not correlate significantly neither with any Positive and Negative Symptom Scale item or subscale, nor with side effects. Drugs other than risperidone were not associated with high prolactin levels. For patients on continuous monotherapy risperidone treatment, there was a marked linear reduction of prolactin level over all 5 years.
CONCLUSION: Risperidone induces a higher prolactin elevation than other atypical antipsychotics, but the effect adapts over time. Prolactin was not associated with expected side effects (e.g. sexual, mental, or weight gain).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355517     DOI: 10.1111/j.1600-0447.2006.00897.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

1.  Prolactin, flupenthixol decanoate and first episode schizophrenia - clinical and laboratory correlates.

Authors:  Mari Retief; Bonginkosi Chiliza; Lebogang Phahladira; Robin Emsley; Laila Asmal
Journal:  Metab Brain Dis       Date:  2019-08-17       Impact factor: 3.584

2.  Antipsychotic-induced sexual dysfunction and its management.

Authors:  Yeon Won Park; Yooseok Kim; Jun Ho Lee
Journal:  World J Mens Health       Date:  2012-12-27       Impact factor: 5.400

3.  Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.

Authors:  Zeynep Kotan; Berrin Ertepe; Cengiz Akkaya; Emre Sarandol; Güven Ozkaya; Selçuk Kirli
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

4.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

5.  PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS.

Authors:  V P Matei; T Purnichi; A Mihailescu; R Grigoras
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

Review 6.  Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.

Authors:  Frank M C Besag; Michael J Vasey; Iffah Salim
Journal:  CNS Drugs       Date:  2021-04-20       Impact factor: 5.749

Review 7.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

8.  Women's sexual dysfunction associated with psychiatric disorders and their treatment.

Authors:  Rosemary Basson; Thea Gilks
Journal:  Womens Health (Lond)       Date:  2018 Jan-Dec

9.  A Comment on "Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia".

Authors:  Ahmed Naguy
Journal:  Indian J Psychol Med       Date:  2018 May-Jun

10.  Prolactin response to antipsychotics: An inpatient study.

Authors:  Liana Dehelean; Ana-Maria Romosan; Ion Papava; Cristina Ana Bredicean; Victor Dumitrascu; Sorin Ursoniu; Radu-Stefan Romosan
Journal:  PLoS One       Date:  2020-02-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.